Perspective: cancer vaccines in the era of immune checkpoint blockade

由 Cebon, Jonathan
發表在 Mamm Genome (2018)

Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti‐PD‐1 Therapy

由 Parakh, Sagun, Cebon, Jonathan, Klein, Oliver
發表在 Oncologist (2018)

Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature

由 Gunjur, Ashray, Klein, Oliver, Kee, Damien, Cebon, Jonathan
發表在 J Immunother Cancer (2019)

Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells

由 Woods, Katherine, Pasam, Anupama, Jayachandran, Aparna, Andrews, Miles C., Cebon, Jonathan
發表在 Front Oncol (2014)

Embryonic Chicken Transplantation is a Promising Model for Studying the Invasive Behavior of Melanoma Cells

由 Jayachandran, Aparna, McKeown, Sonja J., Woods, Briannyn L., Prithviraj, Prashanth, Cebon, Jonathan
發表在 Front Oncol (2015)

A pilot study of intrahepatic yttrium‐90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver‐only metastases

由 Arulananda, Surein, Parakh, Sagun, Palmer, Jodie, Goodwin, Mark, Andrews, Miles C., Cebon, Jonathan
發表在 Cancer Rep (Hoboken) (2019)

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations

由 Vella, Laura J, Andrews, Miles C, Pasam, Anupama, Woods, Katherine, Behren, Andreas, Cebon, Jonathan S
發表在 Oncoimmunology (2014)

Characterising the phenotypic evolution of circulating tumour cells during treatment

由 Tsao, Simon Chang-Hao, Wang, Jing, Wang, Yuling, Behren, Andreas, Cebon, Jonathan, Trau, Matt
發表在 Nat Commun (2018)

Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ()

由 Vella, Laura J., Behren, Andreas, Coleman, Bradley, Greening, David W., Hill, Andrew F., Cebon, Jonathan
發表在 Neoplasia (2017)

A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma

由 Ebert, Lisa M., MacRaild, Sarah E., Zanker, Damien, Davis, Ian D., Cebon, Jonathan, Chen, Weisan
出版 2012

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma

由 Parker, Robert, Vella, Laura J., Xavier, Dylan, Amirkhani, Ardeshir, Parker, Jimmy, Cebon, Jonathan, Molloy, Mark P.
發表在 Front Oncol (2015)

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

由 Chang-Hao Tsao, Simon, Weiss, Jonathan, Hudson, Christopher, Christophi, Christopher, Cebon, Jonathan, Behren, Andreas, Dobrovic, Alexander
發表在 Sci Rep (2015)

Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma

由 Woods, Katherine, Knights, Ashley J., Anaka, Matthew, Schittenhelm, Ralf B., Purcell, Anthony W., Behren, Andreas, Cebon, Jonathan
發表在 J Immunother Cancer (2016)

Systems analysis identifies miR-29b regulation of invasiveness in melanoma

由 Andrews, Miles C., Cursons, Joseph, Hurley, Daniel G., Anaka, Matthew, Cebon, Jonathan S., Behren, Andreas, Crampin, Edmund J.
發表在 Mol Cancer (2016)

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

由 Tutuka, Candani S. A., Andrews, Miles C., Mariadason, John M., Ioannidis, Paul, Hudson, Christopher, Cebon, Jonathan, Behren, Andreas
發表在 Mol Cancer (2017)

Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion

由 Prithviraj, Prashanth, Anaka, Matthew, McKeown, Sonja J, Permezel, Michael, Walkiewicz, Marzena, Cebon, Jonathan, Behren, Andreas, Jayachandran, Aparna
發表在 Oncotarget (2015)

Alternate antigen processing in the presence of gamma interferon may misdirect the immune recognition of cancer

由 Woods, Katherine, Schittenhelm, Ralf B, Heesterbeek, Dani, Knights, Ashley, Anaka, Matthew, Purcell, Anthony W, Behren, Andreas, Cebon, Jonathan
發表在 J Immunother Cancer (2015)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy

由 Prithviraj, Prashanth, McArthur, Grant, Atkinson, Victoria, Parente, Phillip, Andrews, Miles, Parakh, Sagun, Millward, Michael, Cebon, Jonathan, Klein, Oliver
發表在 J Immunother Cancer (2015)

Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report

由 Hultin, Sebastian, Nahar, Kazi, Menzies, Alexander M., Long, Georgina V., Fernando, Suran L., Atkinson, Victoria, Cebon, Jonathan, Wong, Muh Geot
發表在 BMC Nephrol (2020)

Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors

由 Anaka, Matthew, Hudson, Christopher, Lo, Pu-Han, Do, Hongdo, Caballero, Otavia L, Davis, Ian D, Dobrovic, Alexander, Cebon, Jonathan, Behren, Andreas
出版 2013